Sudeep Pharma Limited announced its Q2 FY27 financial results, reporting its highest-ever quarterly revenue of ₹196.7 crore, marking a 21% year-on-year increase. EBITDA also saw substantial growth, rising by 32% to ₹73.2 crore. The company attributes this strong performance to healthy demand across its Pharma, Food & Nutrition, and Specialty Ingredients businesses, supported by a favorable product mix and improved operational efficiencies.
Sudeep Pharma Reports Strong Q2 FY27 Performance
Sudeep Pharma Limited has declared its financial results for the second quarter and half-year ended September 30, 2026, showcasing robust growth and record quarterly performance. The company achieved its highest-ever quarterly revenue of ₹196.7 crore, representing a significant 21% year-on-year increase. Alongside this revenue growth, Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) surged by 32% year-on-year to ₹73.2 crore.
Key Financial Highlights
The company’s Q2 FY27 EBITDA margin stood at 37.2%, an improvement of approximately 70 basis points compared to the previous year. This performance was driven by a favorable product mix and enhanced operating efficiencies across its core business segments: Pharma, Food & Nutrition, and Specialty Ingredients. These segments continued to experience healthy demand in key markets. The company also noted the sustained growth momentum of its value-added portfolio, particularly AbsorBis, attributed to new customer additions and ongoing approvals.
Operational & Strategic Developments
A significant milestone highlighted was the receipt of FDA approval for the Nandesari greenfield facility. With customer qualification processes underway, commercial supplies are anticipated to commence in H2 FY27, enhancing manufacturing capabilities and access to regulated markets. Furthermore, the Sudeep Advanced Materials (SAM) Dahej project is progressing as planned, with Phase 1 capacity targeted for completion by March 2027. The company is also evaluating further capacity expansion for battery-grade iron phosphate.
First Half Performance
For the first half of FY27 (H1 FY27), Sudeep Pharma reported revenue from operations of ₹355.0 crore, an increase of 23% year-on-year. EBITDA for H1 FY27 reached ₹128.1 crore, up 29% year-on-year, with a margin of 36.1%. Profit After Tax (PAT) for H1 FY27 stood at ₹92.4 crore, an 18% increase year-on-year.
Source: BSE
